Jae Sik Shin

Title: Innovations by Jae Sik Shin

Introduction

Jae Sik Shin is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of five patents to his name, his work focuses on biomarkers and methods for predicting sensitivity to various cancer therapies.

Latest Patents

One of Jae Sik Shin's latest patents is a biomarker for predicting the sensitivity to a protein kinase inhibitor. This invention provides a marker, a composition, and a kit for predicting sensitivity to such inhibitors, which can be crucial for effective cancer treatment. The marker has shown excellent efficacy in predicting sensitivity, making it a valuable tool in oncology. Another notable patent involves a combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET). This invention offers a method for predicting susceptibility to MET inhibitors, particularly for stomach and lung cancers, thereby enhancing treatment options for these conditions.

Career Highlights

Throughout his career, Jae Sik Shin has worked with notable organizations, including Wellmarker Bio Co., Ltd. and The Asan Foundation. His experience in these companies has allowed him to develop innovative solutions that address critical challenges in cancer treatment.

Collaborations

Jae Sik Shin has collaborated with several professionals in his field, including Dong Hoon Jin and Seung Woo Hong. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Jae Sik Shin's contributions to biotechnology and cancer treatment through his innovative patents highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in cancer therapies, demonstrating the importance of research and innovation in healthcare.